Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level
Endocrine Journal · 2025
DOI: 10.1507/endocrj.ej24-0696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2025. Verfasst von Takuyuki Katabami und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan. Hauptthemen laut MEDLINE: Cushing Syndrome, Hydrocortisone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Center for Global Health and Medicine, Japan, Ministry of Health, Labour and Welfare of Japan.
Abstract (Originalsprache)
Osilodrostat dosage is adjusted based on 24-h urinary free cortisol (UFC) levels. However, approximately 1 week is required to obtain the results. In contrast, serum cortisol levels are available soon after sampling, allowing the determination of osilodrostat doses promptly. However, this issue remains poorly understood. Therefore, this study aimed to determine whether a simultaneous assay of serum cortisol and UFC concentrations is useful in patients with Cushing syndrome (CS) receiving osilodrostat. This was a retrospective cross-sectional study. A total of 71 paired samples in six patients with CS during osilodrostat treatment were analyzed in this study. The 24-h urine sample collection was started from the day before blood sampling, and UFC and morning serum cortisol levels were measured on the same day. Commercially available immunoassay kits were used for the hormone measurements. A significant positive correlation between morning cortisol levels and UFC levels was observed. Receiver operating characteristic analysis showed a cut-off of 21.5 μg/dL for serum cortisol as the best indicator to predict high UFC levels. The cut-off secured UFC samples >3× the upper limit of normal. However, the positive predictive value of serum cortisol levels in predicting low UFC was considerably low. A serum cortisol level
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Japan.
- Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
Förderung
- National Center for Global Health and Medicine, Japan
- Ministry of Health, Labour and Welfare of Japan
Zitieren
APA
Katabami, T., Matsuba, R., Nagasaka, T., Yamamoto, Y., Sakai, K., & Sone, M. (2025). Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level. Endocrine Journal. https://doi.org/10.1507/endocrj.ej24-0696
Vancouver
Katabami T, Matsuba R, Nagasaka T, Yamamoto Y, Sakai K, Sone M. Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level. Endocrine Journal. 2025. doi:10.1507/endocrj.ej24-0696
BibTeX
@article{Katabami2025,
author = {Katabami, Takuyuki and Matsuba, Ren and Nagasaka, Tomoyuki and Yamamoto, Yutaro and Sakai, Kensuke and Sone, Masakatsu},
title = {Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level},
journal = {Endocrine Journal},
year = {2025},
doi = {10.1507/endocrj.ej24-0696}
}
EUVIMED